New study aims to make HIV prevention shots work better for black women
NCT ID NCT05514509
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study looked at how to best give HIV prevention shots (called CAB PrEP) to Black cis and transgender women in the US. Researchers tested different ways to offer the shots in clinics and asked both patients and staff what worked well and what didn't. The goal was to make it easier for women to get this protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20017, United States
-
GSK Investigational Site
Miami, Florida, 33137, United States
-
GSK Investigational Site
Orlando, Florida, 32808, United States
-
GSK Investigational Site
Tampa, Florida, 33611, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33401, United States
-
GSK Investigational Site
Atlanta, Georgia, 30303, United States
-
GSK Investigational Site
Atlanta, Georgia, 30309, United States
-
GSK Investigational Site
Atlanta, Georgia, 30312, United States
-
GSK Investigational Site
Bridgeport, Kansas, 06605, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89104, United States
-
GSK Investigational Site
Brooklyn, New York, 10001, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19114, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19147, United States
-
GSK Investigational Site
Memphis, Tennessee, 38104, United States
-
GSK Investigational Site
Dallas, Texas, 75201, United States
-
GSK Investigational Site
Houston, Texas, 77006, United States
-
GSK Investigational Site
Houston, Texas, 77021, United States
-
GSK Investigational Site
Norfolk, Virginia, 23510, United States
Conditions
Explore the condition pages connected to this study.